Natco Pharma

Natco Pharma
Traded as	NSE: NATCOPHARM ; BSE: 524816
Industry	Pharmaceuticals
Founded	1981
Founder(s)	VC Nannapaneni
Headquarters	Hyderabad, Telangana, India
Area served	Global
Key people	VC Nannapaneni (Chairman and MD); Rajeev Nannapaneni (CEO and Vice Chairman)
Revenue	₹2,155 crore (US$300 million) (FY2021)
Website	natcopharma.co.in

Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and crop health science products, and also provides contract manufacturing services.^[3] It is a major producer of branded oncology medicines^[4] and hepatitis C drugs.^[5] The company specialises in producing complex medicines at affordable prices.^[6]^[7] In 2019, Natco launched its crop health sciences division.^[8]^[9]

History[edit]

In 2003, Natco Pharma launched Veenat, a generic version of Novartis AG's anti-cancer drug Glivec. It won the subsequent patent protection legal battle against Novartis in 2013.^[10]
In 2012, Natco Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.^[5]
In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.^[10]
In 2015, Natco Pharma started production of Sofosbuvir in Nepal.^[11]
In 2016, Natco Pharma launched the first Tamiflu capsule in the US market.^[12]
In 2017, Natco Pharma launched a generic version of blood cancer drug Pomalidomide at a 98% discount to the drug's selling price in the United States.^[13]
In 2019, Natco Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.^[14]

External links[edit]

Official website

References[edit]

↑ "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.
↑ "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.
↑ "Our Business | Natco Pharma". Retrieved 25 April 2022.
↑ "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.
↑ ^5.0 ^5.1 "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.
↑ PTI (17 December 2020). "Natco Pharma launches anti blood clot medication, Rivaroxaban, in India". The Economic Times. Retrieved 25 April 2022.
↑ Akolkar, Shrikant (9 March 2017). "Natco Pharma: Top league player" (PDF). Angel One. Retrieved 25 April 2022.
↑ "Mission & Heritage | Natco Pharma". Retrieved 25 April 2022.
↑ Sridhar, G. Naga (25 November 2020). "Natco Pharma expects agri business to be key growth lever". www.thehindubusinessline.com. Retrieved 24 April 2022.
↑ ^10.0 ^10.1 "Niche Play". Business Today. Retrieved 19 April 2020.
↑ "Natco Pharma History | Natco Pharma Information". The Economic Times. Retrieved 3 February 2022.
↑ "Bayer cancer drug faces new Nexavar patent problems in India". www.thepharmaletter.com. Retrieved 3 February 2022.
↑ "Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price – Business News , Firstpost". Firstpost. 10 May 2017. Retrieved 31 July 2020.
↑ "Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra". 25 January 2019.

Dear reader, We kindly request your support in maintaining the independence of Bharatpedia. As a non-profit organization, we rely heavily on small donations to sustain our operations and provide free access to reliable information to the world. We would greatly appreciate it if you could take a moment to consider donating to our cause, as it would greatly aid us in our mission. Your contribution would demonstrate the importance of reliable and trustworthy knowledge to you and the world. Thank you.

Please select an option below or scan the QR code to donate
₹150 ₹500 ₹1,000 ₹2,000 ₹5,000 ₹10,000 Other

[1] "Facing headwinds in US, Natco Pharma looks to scale up business in China". Livemint. Retrieved 19 April 2020.

[2] "Natco Pharma: In fine fettle". Forbes India. Retrieved 19 April 2020.

[:0-3] "Our Business | Natco Pharma". Retrieved 25 April 2022.

[paraiv-4] "Natco Pharma lines up 20 'Para IV' products". The Hindu Business Line. Retrieved 19 April 2020.

[ladder-5] 5.0 ^5.1 "How Natco defied the odds to rise up India's pharma ladder". Moneycontrol. Retrieved 19 April 2020.

[6] PTI (17 December 2020). "Natco Pharma launches anti blood clot medication, Rivaroxaban, in India". The Economic Times. Retrieved 25 April 2022.

[7] Akolkar, Shrikant (9 March 2017). "Natco Pharma: Top league player" (PDF). Angel One. Retrieved 25 April 2022.

[8] "Mission & Heritage | Natco Pharma". Retrieved 25 April 2022.

[9] Sridhar, G. Naga (25 November 2020). "Natco Pharma expects agri business to be key growth lever". www.thehindubusinessline.com. Retrieved 24 April 2022.

[niche-10] 10.0 ^10.1 "Niche Play". Business Today. Retrieved 19 April 2020.

[11] "Natco Pharma History | Natco Pharma Information". The Economic Times. Retrieved 3 February 2022.

[12] "Bayer cancer drug faces new Nexavar patent problems in India". www.thepharmaletter.com. Retrieved 3 February 2022.

[13] "Natco Pharma launches blood cancer drug priced Rs 5,000–20,000, down 98% from US price – Business News , Firstpost". Firstpost. 10 May 2017. Retrieved 31 July 2020.

[14] "Natco Pharma to invest Rs 100 cr for setting up agrichemical facilities in Andhra". 25 January 2019.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]